The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149.
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; Incyte; Incyte; Incyte; Incyte; ipsen; ipsen; ipsen; ipsen; LEK; LEK; LEK; LEK; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; M3; M3; M3; M3; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Jens C. Eickhoff
Consulting or Advisory Role - Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics
 
Chandrikha Chandrasekharan
No Relationships to Disclose
 
Shadia Ibrahim Jalal
Research Funding - Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Tesaro; Tesaro; Tesaro; Tesaro
 
Al Bowen Benson
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AXIO Research; AXIO Research; AXIO Research; AXIO Research; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Guardant Health; Guardant Health; Guardant Health; Guardant Health; inVentiv Health; inVentiv Health; inVentiv Health; inVentiv Health; Lilly; Lilly; Lilly; Lilly; LSK BioPharma; LSK BioPharma; LSK BioPharma; LSK BioPharma; Merck; Merck; Merck; Merck; NCCN; NCCN; NCCN; NCCN; Purdue Pharma; Purdue Pharma; Purdue Pharma; Purdue Pharma; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Terumo; Terumo; Terumo; Terumo; TheraBionic; TheraBionic; TheraBionic; TheraBionic
Research Funding - Acerta Pharma; Acerta Pharma; Acerta Pharma; Acerta Pharma; advanced accelerator applications (Inst); advanced accelerator applications (Inst); advanced accelerator applications (Inst); advanced accelerator applications (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); MedImmune; MedImmune; MedImmune; MedImmune; Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Xencor; Xencor; Xencor; Xencor
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Guardant Health; Guardant Health; Guardant Health; Guardant Health; guerbet; guerbet; guerbet; guerbet; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Sanofi; Sanofi; Sanofi; Sanofi; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; TRM Oncology; TRM Oncology; TRM Oncology; TRM Oncology
 
Dustin A. Deming
Consulting or Advisory Role - Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Novocure; Novocure; Novocure; Novocure; Promega; Promega; Promega; Promega; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Stephen Lindemann
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis; Genentech; Genentech; Genentech; Genentech